Detalles de la búsqueda
1.
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 90(2): 606-612, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37897064
2.
Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
Br J Clin Pharmacol
; 89(9): 2691-2702, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055941
3.
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Br J Clin Pharmacol
; 88(4): 1942-1946, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687551
4.
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Circulation
; 142(11): 1040-1054, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673497
5.
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
Diabetes Obes Metab
; 23(5): 1101-1110, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33394543
6.
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
J Pharmacol Exp Ther
; 375(1): 76-91, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32764153
7.
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
Diabetes Obes Metab
; 22(12): 2493-2498, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803900
8.
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Diabetes Obes Metab
; 22(5): 798-806, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912603
9.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovasc Diabetol
; 18(1): 138, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31640705
10.
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
Diabetes Obes Metab
; 21(6): 1381-1387, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30756462
11.
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Diabetes Obes Metab
; 21(4): 876-882, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30499157
12.
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
Diabetes Obes Metab
; 21(4): 829-836, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30456904
13.
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Diabetes Obes Metab
; 21(12): 2667-2673, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407856
14.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Diabetes Obes Metab
; 21(12): 2684-2693, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31423699
15.
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Am J Physiol Renal Physiol
; 315(5): F1295-F1306, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019930
16.
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Diabetes Obes Metab
; 20(3): 479-487, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024278
17.
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
Diabetes Obes Metab
; 20(8): 2034-2038, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29663628
18.
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Cardiovasc Diabetol
; 16(1): 113, 2017 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28903775
19.
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Antimicrob Agents Chemother
; 60(5): 2782-9, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902761
20.
Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies.
Anal Chem
; 87(6): 3247-54, 2015 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25671589